Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced its upcoming participation in two major investor conferences in March 2025.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Avadel Pharmaceuticals (Nasdaq: AVDL) has announced its upcoming participation in two major investor conferences in March 2025. The company will be featured in:
- A fireside chat at the Leerink Global Biopharma Conference on Wednesday, March 12 at 9:20 a.m. ET
- A fireside chat at the UBS Virtual CNS Day on Monday, March 17 at 8:30 a.m. ET
Both events will be accessible through live webcasts on Avadel's Investor Relations website (investors.avadel.com), with recordings remaining available for 90 days after each conference.
Details
News Market Reaction – AVDL
The recorded move for AVDL in the trading session of this news was +3.01%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DUBLIN, Ireland, March 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences:
- Leerink Global Biopharma Conference: Fireside chat on Wednesday, March 12 at 9:20 a.m. ET.
- UBS Virtual CNS Day: Fireside chat on Monday, March 17 at 8:30 a.m. ET.
A live webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionAQ.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.